Published in Mol Cell Biol on November 01, 1999
p53 and metabolism. Nat Rev Cancer (2009) 5.05
p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J (2003) 1.68
Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol (2008) 1.27
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J (2006) 1.26
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
Mitochondrial dysfunction impairs tumor suppressor p53 expression/function. J Biol Chem (2011) 0.95
TIGAR, TIGAR, burning bright. Cancer Metab (2014) 0.91
The biology of lysine acetylation integrates transcriptional programming and metabolism. Nutr Metab (Lond) (2011) 0.87
Cancer stem cell theory and the warburg effect, two sides of the same coin? Int J Mol Sci (2014) 0.87
NAD+ modulates p53 DNA binding specificity and function. Mol Cell Biol (2004) 0.85
Uncovering the basis of ATP hydrolysis activity in purified human p53 protein: a reinvestigation. PLoS One (2014) 0.75
Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J (1982) 38.14
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
p53: puzzle and paradigm. Genes Dev (1996) 13.16
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
G protein mechanisms: insights from structural analysis. Annu Rev Biochem (1997) 6.41
DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol (1994) 4.14
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev (1993) 3.99
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev (1996) 3.61
p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 3.19
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science (1994) 2.98
Yeast and mammalian ras proteins have conserved biochemical properties. Nature (1985) 2.85
Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol (1995) 2.75
p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev (1993) 2.74
The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell (1997) 2.64
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet (1995) 2.47
Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol (1994) 2.44
Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A (1995) 2.43
Molecular matchmakers. Science (1993) 2.25
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol (1991) 2.20
p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J (1993) 2.16
Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell (1995) 2.13
p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell (1995) 2.06
How p53 binds DNA as a tetramer. EMBO J (1998) 1.82
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63
Mismatch repair, molecular switches, and signal transduction. Genes Dev (1998) 1.59
The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J (1995) 1.58
The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A (1995) 1.52
Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc Natl Acad Sci U S A (1995) 1.42
Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. J Biol Chem (1991) 1.34
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res (1995) 1.33
Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene (1998) 1.31
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene (1998) 1.28
Human p53 binds Holliday junctions strongly and facilitates their cleavage. J Biol Chem (1997) 1.25
Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element. J Biol Chem (1997) 1.18
An ATP-ADP switch in MuB controls progression of the Mu transposition pathway. EMBO J (1998) 1.08
Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene (1994) 1.06
Electron-paramagnetic-resonance studies of manganese(II) complexes with elongation factor Tu from Bacillus stearothermophilus. Observation of a GTP hydrolysis intermediate state complex. Eur J Biochem (1984) 1.01
Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding. Oncogene (1996) 0.95
Wildtype p53 is required for heat shock and ultraviolet light enhanced repair of a UV-damaged reporter gene. Carcinogenesis (1997) 0.91
Signalling to p53: where does it all start? Bioessays (1996) 0.90
The oligomerization domain of p53: crystal structure of the trigonal form. FEBS Lett (1996) 0.88
Specific p53-DNA complexes contain an mdm2-related protein. Oncogene (1997) 0.81
[The human adenosine deaminase gene contains a p53-responsive element]. Dokl Akad Nauk (1996) 0.77
On Edwards' criterion of seasonality and a non-parametric alternative. Br J Prev Soc Med (1971) 4.19
Transcriptional activation functions in BRCA2. Nature (1997) 3.86
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Am J Clin Nutr (1979) 3.84
SV40-53K antigen: a possible role for 53K in normal cells. Virology (1981) 3.46
Source of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Carbohydrate sources, vitamins, and minerals. Am J Clin Nutr (1983) 2.43
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (1984) 1.97
A new indicator of human malignant tumour. Br J Cancer (1984) 1.60
Small mammal survival and trapability in mark-recapture monitoring programs for hantavirus. J Wildl Dis (1998) 1.49
Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. Oncogene (2000) 1.46
BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene (1998) 1.34
A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res (1993) 1.33
Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J (1992) 1.33
Specific DNA binding by different classes of human p53 mutants. Oncogene (1995) 1.31
Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol (1997) 1.30
Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J (1993) 1.25
Drug-related deaths in the United States--first decade of an epidemic. Health Serv Rep (1974) 1.23
Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer (1990) 1.21
Incidental appendectomy: a statistical appraisal. Can Med Assoc J (1969) 1.20
Racial differences in the incidence of congenital hypothyroidism. J Pediatr (1981) 1.20
The cellular tumour antigen p53: evidence for transformation-related, immunological variants of p53. Virology (1986) 1.15
Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene (2006) 1.10
Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene (1994) 1.09
Monoclonal antibody which agglutinates erythrocytes from cancer patients. Lancet (1982) 1.07
Dielectric relaxation measurements of 12 kbp plasmid DNA. Biochim Biophys Acta (2000) 1.03
Chain transplantation: initial experience of a large multicenter program. Am J Transplant (2012) 1.02
Wild-type p53 protein shows calcium-dependent binding to F-actin. Oncogene (1999) 1.02
Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement. J Neurol Neurosurg Psychiatry (2005) 1.00
Evidence that immunological variants of p53 represent alternative protein conformations. Virology (1988) 0.98
Lymphocyte stimulation: concanavalin A induces the expression of a 53K protein. Cell Biol Int Rep (1980) 0.96
Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding. Oncogene (1996) 0.95
The dollar cost of patient assault. Hosp Community Psychiatry (1989) 0.95
Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene (1992) 0.93
Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism. Oncogene (1995) 0.92
Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene (1993) 0.91
p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress. Oncogene (2001) 0.91
p47phox-deficient immune microenvironment signals dysregulate naive T-cell apoptosis. Cell Death Differ (2008) 0.91
Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol (2011) 0.91
Some proposed "comparability areas" for U. S. statistics on cause of death. Public Health Rep (1969) 0.90
Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene (1998) 0.90
Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene (1992) 0.89
The occurrence and treatment of gallbladder disease in Ontario. J Chronic Dis (1972) 0.88
Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. Oncogene (1998) 0.88
Molecular targets for selenium in cancer prevention. Nutr Cancer (2001) 0.88
p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene (1995) 0.88
A twin study examining the genetic influence on food selection. Hum Nutr Appl Nutr (1983) 0.88
Inequality of the services received by individuals: a suggested index and an illustrative application. Med Care (1975) 0.87
Crosstalk between site-specific modifications on p53 and histone H3. Oncogene (2007) 0.87
Acute humoral rejection in an ABO compatible combined liver-kidney transplant--the kidney is not always protected. Am J Transplant (2009) 0.87
Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br J Cancer (1995) 0.87
Analysis of nucleotide excision repair by detection of single-stranded DNA transients. Carcinogenesis (2001) 0.87
The SV40 large T-p53 complex: evidence for the presence of two immunologically distinct forms of p53. Virology (1985) 0.86
Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. Exp Cell Res (2000) 0.86
Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry (1994) 0.85
Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene (1997) 0.85
Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. Immunol Lett (1990) 0.85
Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site. Oncogene (1994) 0.84
Heritability of "sinking" pre-beta lipoprotein level: a twin study. Clin Genet (1977) 0.84
Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53. Oncogene (1995) 0.83
Weight of horses: improved estimates based on girth and length. Can Vet J (1969) 0.83
Visualisation, by immunocytochemistry, of p53 at the plasma membrane of both nontransformed and SV40-transformed cells. Virology (1986) 0.83
Is protein synthesis necessary for the commitment of lymphocyte transformation? Nature (1978) 0.83
The inheritance of sinking-pre-beta lipoprotein and its relation to the Lp(a) antigen. Clin Genet (1982) 0.81
Specific p53-DNA complexes contain an mdm2-related protein. Oncogene (1997) 0.81
Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2R alpha, krox-24, p53, hsc70 and cyclophilin. Immunology (1992) 0.81
Nutrition economics - food as an ally of public health. Br J Nutr (2013) 0.81
Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer (1999) 0.80
Increased salt concentration reversibly destabilizes p53 quaternary structure and sequence-specific DNA binding. Biochem J (1994) 0.80
The growth of Malawian preschool children from different socioeconomic groups. Eur J Clin Nutr (1995) 0.80
Evidence for a physiological regulation of food selection and nutrient intake in twins. Am J Clin Nutr (1981) 0.80
Comparative study of the enzyme activities of Borrelia burgdorferi and other non-intestinal and intestinal spirochaetes. New Microbiol (1995) 0.80
A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein. Oncogene (1999) 0.80
Selenium content and glutathione peroxidase activity of milk from vegetarian and nonvegetarian women. J Nutr (1989) 0.79
Proteolytic cleavage of p53: a model for the activation of p53 in response to DNA damage. Oncol Res (1997) 0.79
Proteolytic cleavage of p53 mutants in response to mismatched DNA. Br J Cancer (1999) 0.79
Nursing staff characteristics related to patient assault. Issues Ment Health Nurs (1991) 0.79
A twin study on the heritability of lipoprotein fractions. Acta Genet Med Gemellol (Roma) (1976) 0.78
Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. Transplantation (1991) 0.78
The functional development of mammalian mitochondria. Biol Rev Camb Philos Soc (1976) 0.78
FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. Transplant Proc (1990) 0.77
Seasonal influences on the risk of cardiac malformation. Nature of the problem and some results from a study of 10,077 cases. Int J Epidemiol (1972) 0.77
Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo. Br J Cancer (1998) 0.77
Prevalence of hemophilia in Ontario, 1966. Can Med Assoc J (1970) 0.75
Communication: clothes maketh a patient. Nurs Mirror (1982) 0.75
Proceedings: Studies of the metabolism of a dextrin, caloreen administered intravenously in human subjects. Clin Sci Mol Med (1974) 0.75
Predictors of patient assault on acute inpatient psychiatric units: a pilot study. Issues Ment Health Nurs (1988) 0.75
Killing of mice by rats: suppression by medial hypothalamic stimulation. Physiol Behav (1978) 0.75
Management of infant sleeping problems. Midwife Health Visit Community Nurse (1982) 0.75
Uses of the surname in epidemiologic research. Am J Epidemiol (1972) 0.75
Intravenous infusion of a dextrin, Caloreen, in human subjects: metabolic studies. Br J Nutr (1977) 0.75
Kidney preservation using combinations of Belzer and Collins techniques. Transplantation (1975) 0.75
Plasma lipid variability in the Toronto Twin Register. Acta Genet Med Gemellol (Roma) (1980) 0.75
Early discharge of maternity patients. Can Hosp (1970) 0.75
Customary diet, anthropometry, and dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation (1986) 0.75
Coordinated system for comprehensive newborn metabolic screening. South Med J (1982) 0.75
An inducible gene involved in commitment of lymphocytes to transform. Nature (1978) 0.75
Towards a general monitoring system for length of stay. Can Hosp (1970) 0.75
Environmental characteristics related to patient assault. Issues Ment Health Nurs (1995) 0.75
Components of the demand for hospital care. Int J Epidemiol (1972) 0.75